Target intelligence / Profile preview

Venom toxin protein

Molecular classification
Enzyme, Ion channel modulator, Receptor ligand, Protease inhibitor, Phospholipase, Metalloprotease, Neurotoxin, Three-finger toxin (3FTx), C-type lectin (Snaclec)
01

Overview

Venom toxin proteins comprise a highly diverse group of bioactive proteins found in animal venoms, primarily in snakes, but also in spiders, scorpions, and cone snails. These toxins are classified into families such as phospholipase A2, metalloproteases, serine proteases, three-finger toxins, and C-type lectins, among many others[2][4]. They exert their effects via enzymatic activity, modulation of blood coagulation, neurotoxic and cytotoxic actions, and interference with physiological signaling in victims[1][3]. These proteins are studied for their potential as pharmacological tools, drug leads, and as targets for antivenom development, but "Venom toxin proteins" is too broad to be used as a specific therapeutic target or receptor. Each protein family and even individual toxins within venom can have unique structure, activity, and pharmacological significance[2][3][5][7]. To obtain structured, actionable information, future queries should specify an individual toxin or protein family (e.g., "Phospholipase A2 from Bothrops snake venom" or "Three-finger toxin from cobra venom"), rather than the generic category "Venom toxin proteins".

Other names
Snake venom proteinAnimal venom toxinVenom peptideToxin protein
02

Mechanism of action

Enzymatic cleavage of physiological substrates (e.g., proteases, phospholipases)[1][3] Inhibition or activation of ion channels (e.g., dendrotoxin blocks Kv1 potassium channels)[5][6] Binding to receptor proteins and interference with signaling pathways Disruption of cell membranes (cytolytic action)

03

Biological functions

NeurotoxicityCytotoxicityBlood coagulation modulationImmune system modulationIon channel inhibitionEnzymatic digestionSignal transduction interferenceCell death induction
04

Disease associations

Envenomation (toxic effects following animal bite/sting)HemorrhageParalysisPain/inflammationCardiovascular collapseRare use in cancer research (drug leads)
05

Safety considerations

High toxicity to humans and animalsImmunogenicity (risk of allergic reaction to antivenoms)Therapeutic challenge in neutralizing diverse toxin isoformsDifficulty in developing small molecule antidotes due to toxin diversity[7]
06

Interacting drugs

Antivenoms (polyclonal antibodies)

1 more in the full profile.

Beyond the preview

Go deeper on Venom toxin protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Venom toxin protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call